For the quarter ending 2026-03-31, WHWK had -$2,778K decrease in cash & cash equivalents over the period. -$22,208K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net (loss) income | -22,194 | -23,251 | 2,655 | - |
| Share-based compensation expense | 2,193 | 2,388 | 2,718 | 4,767 |
| Gain on sale of business | 0 | 0 | 87,266 | - |
| Discount amortization on short-term investments | 347 | 831 | 717 | -21 |
| Non-cash interest expense | - | - | 0 | 0 |
| Non-cash lease expense | 0 | 0 | 0 | 74 |
| Depreciation and amortization expense | - | 79 | - | - |
| Depreciation expense | -77 | - | 5 | 73 |
| Accounts receivable | 0 | 0 | 0 | 1,000 |
| Inventory | 0 | 0 | 0 | -170 |
| Prepaid expenses and other current assets | -1,470 | 375 | 965 | -906 |
| Other non-current assets | -163 | -163 | -165 | 766 |
| Operating lease liabilities | 0 | 0 | 0 | -89 |
| Accounts payable and accrued liabilities | -3,494 | 4,671 | 985 | -1,733 |
| Other liabilities | 0 | 0 | 0 | -202 |
| Net cash used in operating activities | -22,208 | -17,234 | -15,378 | -64,821 |
| Proceeds from sale of business, net cash, cash equivalents, and restricted cash | 0 | 0 | -70 | 101,356 |
| Purchases of property and equipment | 0 | 0 | 0 | 552 |
| Purchase of short-term investments | 19,186 | 22,918 | 93,555 | 32,215 |
| Maturity of short-term investments | 38,616 | 39,764 | 1,998 | 18,083 |
| Net cash provided by investing activities | 19,430 | 16,846 | -91,627 | 86,672 |
| Proceeds from sale of common stock and prefunded warrants in pipe financing | 0 | 0 | 0 | 100,002 |
| Proceeds from issuance under employee stock purchase plan | - | 25 | 0 | 24 |
| Issuance of common stock upon exercise of stock options | 0 | 0 | 0 | 26 |
| Payment of pipe financing related transaction costs | 0 | 0 | 0 | 5,625 |
| Deferred offering costs paid for financing | - | 0 | 0 | 76 |
| Net cash provided by financing activities | 0 | 25 | 0 | 94,351 |
| Net (decrease) increase in cash and cash equivalents | -2,778 | -363 | -107,005 | 116,202 |
| Cash, cash equivalents and restricted cash, beginning of period | 37,568 | 37,931 | 28,734 | - |
| Cash and cash equivalents, end of period | 34,790 | 37,568 | 37,931 | - |
Whitehawk Therapeutics, Inc. (WHWK)
Whitehawk Therapeutics, Inc. (WHWK)